Pepgen INC Form 4 insider transactions

James G. McArthur, President and CEO of PepGen Inc., reports acquisition of shares and stock options.

Mary Beth DeLena, General Counsel of PepGen Inc., reports acquiring shares through performance-based stock units and subsequently selling a portion to cover tax obligations.

Chief Financial Officer Noel Donnelly of PepGen Inc. reports acquisition of shares through performance-based stock units (PSUs) and subsequent sale to cover tax obligations.

Paul Streck, EVP, Head of R&D at PepGen Inc., reports the acquisition of stock options as part of an inducement plan.

Michelle Mellion, Chief Medical Officer of PepGen Inc., reports the sale of common stock and exercise of stock options under a pre-arranged 10b5-1 trading plan.

Michelle Mellion, Chief Medical Officer of PepGen Inc., exercised stock options and sold shares of common stock on July 18, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Michelle Mellion, Chief Medical Officer of PepGen Inc., exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Michelle L. Mellion, Chief Medical Officer of PepGen Inc., executed stock option exercises and sales on July 1st and 2nd, 2024, under a pre-arranged 10b5-1 trading plan.

Chief Medical Officer of PepGen Inc., Michelle Mellion, reports the sale and acquisition of common stock and stock options under a pre-arranged Rule 10b5-1 trading plan.

RA Capital Management and related entities report changes in beneficial ownership of PepGen Inc. securities, including the grant of stock options to a director.

Director Heidi Henson acquired 13,000 stock options in PepGen Inc. on June 20, 2024.

Director Laurie Keating acquired 13,000 stock options in PepGen Inc. on June 20, 2024.

Director Joshua Resnick acquired 13,000 stock options in PepGen Inc. but disclaims beneficial ownership due to an arrangement with RA Capital Management.

Director Christopher Ashton acquired 13,000 stock options in PepGen Inc. on June 20, 2024, according to a Form 4 filing.

Director Howard Mayer acquired stock options for 8,667 shares of PepGen Inc. on June 20, 2024.

Director Habib J Dable of PepGen Inc. reports the acquisition of 13,000 stock options at an exercise price of $16.80 on June 20, 2024.

Michelle Mellion, Chief Medical Officer of PepGen Inc., exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Michelle L. Mellion, SVP of Clinical Development at PepGen Inc., executed stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Niels Svenstrup, SVP of Chemical Manufacturing & Controls at PepGen Inc., sold 10,000 shares of common stock on May 17, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Oxford Science Enterprises plc files an amendment to its original Form 4 from May 10, 2022, to include a previously omitted purchase of 879,970 shares of PepGen Inc.

SVP, Chemical Manufacturing & Controls at PepGen Inc., Niels Svenstrup, reports the acquisition of stock options.

PepGen Inc.'s CEO, James G McArthur, acquired 300,000 stock options on March 1, 2024, at an exercise price of $16.62.

Noel Donnelly, CFO of PepGen Inc., was granted stock options to purchase 144,000 shares of common stock.

Michelle L. Mellion, SVP of Clinical Development at PepGen Inc., reports the acquisition of stock options.